Literature DB >> 17520333

The protective effect of a purified extract of Withania somnifera against doxorubicin-induced cardiac toxicity in rats.

A Hamza1, A Amin, S Daoud.   

Abstract

The therapeutic value of doxorubicin as an effective antineoplastic agent is limited by its cardiotoxic side-effects. The administration of doxorubicin (10 mg/kg) to male Wistar rats induced necrosis and apoptosis in heart tissues. It also caused oxidative stress damage as evidenced by the elevation of malondialdehyde and protein carbonyl levels and catalase activity, accompanied by the concurrent depletion of total antioxidant capacity and of superoxide dismutase level in cardiac tissues. The doxorubicin-induced cardiotoxicity and oxidative stress damage were also accompanied by increases of myeloperoxidase activity, total calcium content, and the expression of Bcl-2 protein in heart tissues. Most of these doxorubicin-induced biochemical and histological alterations were effectively attenuated by prior administration of purified standardized extract (1.5% withanolides; manufactured by Idea Sphere Inc., American Fork, UT, USA) of Withania somnifera (300 mg/kg). Thus, Withania may play a role in the protection against cardiotoxicity and thus might be a useful adjuvant therapy where doxorubicin is the cancer-treating drug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17520333     DOI: 10.1007/s10565-007-9016-z

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  11 in total

Review 1.  Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.

Authors:  Laura A A Gilliam; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2011-06-15       Impact factor: 8.401

Review 2.  Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone.

Authors:  Avani R Vyas; Shivendra V Singh
Journal:  AAPS J       Date:  2013-09-18       Impact factor: 4.009

Review 3.  Pharmacologic overview of Withania somnifera, the Indian Ginseng.

Authors:  Nawab John Dar; Abid Hamid; Muzamil Ahmad
Journal:  Cell Mol Life Sci       Date:  2015-08-26       Impact factor: 9.261

4.  Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells.

Authors:  Su-Hyeong Kim; Shivendra V Singh
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-13

5.  Melissa officinalis Protects against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 Cells.

Authors:  Alaaeldin Ahmed Hamza; Mahguob Mohamed Ahmed; Hanan Mohamed Elwey; Amr Amin
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

6.  Oral administration of Ginsenoside Rg1 prevents cardiac toxicity induced by doxorubicin in mice through anti-apoptosis.

Authors:  Chen Zhu; Yi Wang; Hua Liu; Haiman Mu; Yue Lu; Jiayi Zhang; Jianhua Huang
Journal:  Oncotarget       Date:  2017-07-31

Review 7.  Reversal of Doxorubicin-induced Cardiotoxicity by Using Phytotherapy: A Review.

Authors:  Azar Hosseini; Amirhossein Sahebkar
Journal:  J Pharmacopuncture       Date:  2017-08-22

Review 8.  Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases.

Authors:  Mahvash Hesari; Pantea Mohammadi; Fatemeh Khademi; Dareuosh Shackebaei; Saeideh Momtaz; Narges Moasefi; Mohammad Hosein Farzaei; Mohammad Abdollahi
Journal:  Int J Nanomedicine       Date:  2021-05-11

9.  Cardioprotective effect of Vedic Guard against doxorubicin-induced cardiotoxicity in rats: A biochemical, electrocardiographic, and histopathological study.

Authors:  Basavaraj C Koti; Shweta Nagathan; Agadihiremath Vishwanathswamy; Pramod C Gadad; Agadihiremath Thippeswamy
Journal:  Pharmacogn Mag       Date:  2013-04       Impact factor: 1.085

10.  Ursolic acid prevents doxorubicin-induced cardiac toxicity in mice through eNOS activation and inhibition of eNOS uncoupling.

Authors:  Haiman Mu; Haiwen Liu; Jiayi Zhang; Jianhua Huang; Chen Zhu; Yue Lu; Yueping Shi; Yi Wang
Journal:  J Cell Mol Med       Date:  2019-01-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.